[Fundamental cardiac and vascular effects of Ca++-antagonistic coronary drugs].
D000200:Action Potentials; D000255:Adenosine Triphosphate / Q000378:metabolism; D000818:Animals; D001692:Biological Transport; D002118:Calcium / Q000037:antagonists & inhibitors* / Q000502:physiology; D002415:Cats; D055598:Chemical Phenomena; D002621:Chemistry; D003331:Coronary Vessels / Q000187:drug effects*; D004110:Diltiazem / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005711:Gallopamil / Q000494:pharmacology; D006168:Guinea Pigs; D006321:Heart / Q000187:drug effects*; D066298:In Vitro Techniques; D009200:Myocardial Contraction / Q000187:drug effects; D009206:Myocardium / Q000378:metabolism; D009543:Nifedipine / Q000494:pharmacology; D010101:Oxygen Consumption / Q000187:drug effects; D010627:Phenethylamines / Q000494:pharmacology; D011299:Prenylamine / Q000494:pharmacology; D011817:Rabbits; D013552:Swine; D014700:Verapamil / Q000494:pharmacology
D010627:Phenethylamines; D005711:Gallopamil; D000255:Adenosine Triphosphate; D014700:Verapamil; D004110:Diltiazem; D009543:Nifedipine; D011299:Prenylamine; D002118:Calcium
Fundamentale Herz- und Gefässwirkungen Ca++-antagonistischer Koronartherapeutika